HR4752119th CongressWALLET

Reducing Hereditary Cancer Act

Sponsored By: Representative Wasserman Schultz

Introduced

Summary

Expands Medicare coverage for hereditary cancer genetic testing and related preventive care. It would let Medicare cover germline mutation testing, repeat tests, guideline-based risk-reducing surgeries, and more frequent high-risk screenings for people with personal or family histories that suggest hereditary cancer.

Show full summary
  • Patients with a personal or family history suspicious for hereditary cancer would be eligible for Medicare-covered germline mutation testing that follows evidence-based clinical practice guidelines. Repeat testing would also be allowed when appropriate.
  • People with identified hereditary cancer mutations would have guideline-recommended risk-reducing surgeries covered as medically necessary under Medicare.
  • Individuals identified at high genetic risk would qualify for more frequent evidence-based screenings such as screening mammography, breast MRI, colonoscopy, and PSA testing, with coverage aligned to guidelines and at least annually.
  • National oncology organizations, including the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the Society of Gynecologic Oncology would guide testing and screening standards, and Medicare contractors may adopt the least restrictive guideline when recommendations conflict.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

More Medicare coverage for hereditary cancer

Medicare would cover genetic tests for inherited cancer if your or your family's history suggests it, including repeat tests. Tests and care must follow evidence-based guidelines from major oncology groups, using the least restrictive standard if guidelines conflict. If testing shows an inherited cancer gene, Medicare would cover risk-reducing surgery when guidelines recommend it. It would also cover screenings at least yearly, including mammograms, breast MRI, colonoscopy, and PSA tests. Changes would start for services after enactment.

Sponsors & CoSponsors

Sponsor

Wasserman Schultz

FL • D

Cosponsors

  • Miller-Meeks

    IA • R

    Sponsored 7/23/2025

  • Schrier

    WA • D

    Sponsored 7/23/2025

  • Buchanan

    FL • R

    Sponsored 7/23/2025

  • Cohen

    TN • D

    Sponsored 8/8/2025

  • Dingell

    MI • D

    Sponsored 8/8/2025

  • Gottheimer

    NJ • D

    Sponsored 8/8/2025

  • Simon

    CA • D

    Sponsored 8/8/2025

  • Carson

    IN • D

    Sponsored 8/8/2025

  • Del. Norton, Eleanor Holmes [D-DC-At Large]

    DC • D

    Sponsored 8/15/2025

  • Bonamici

    OR • D

    Sponsored 8/19/2025

  • Cisneros

    CA • D

    Sponsored 10/10/2025

  • Nunn (IA)

    IA • R

    Sponsored 11/7/2025

  • McBride

    DE • D

    Sponsored 12/9/2025

  • Fitzpatrick

    PA • R

    Sponsored 2/9/2026

  • Kennedy (NY)

    NY • D

    Sponsored 2/9/2026

  • Tonko

    NY • D

    Sponsored 2/9/2026

  • Goldman (NY)

    NY • D

    Sponsored 2/9/2026

  • Bacon

    NE • R

    Sponsored 2/13/2026

  • Matsui

    CA • D

    Sponsored 2/13/2026

  • Dean (PA)

    PA • D

    Sponsored 3/19/2026

  • Hayes

    CT • D

    Sponsored 3/19/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in